AbbVie stock price closes higher on Moody’s upgrade — what ABBV bulls and bears watch next
AbbVie shares closed up 2.0% at $223.43 on Friday after Moody’s upgraded its credit rating to A2 with a stable outlook, citing strong execution in immunology and neuroscience. Focus next week remains on demand and pricing for Skyrizi and Rinvoq as the company navigates post-Humira competition and pricing pressures.